An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

El Dika Imane; Lim Ho Yeong; Yong Wei Peng; Lin Chia-Chi; Yoon Jung-Hwan; Modiano Manuel; Freilich Bradley; Choi Hye Jin; Chao Tsu-Yi; Kelley Robin K.; Brown Joanne; Knox Jennifer; Ryoo Baek-Yeol; Yau Thomas; Abou-Alfa Ghassan K.

首页> 外文期刊>The oncologist >An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

【24h】

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

机译：开放标签，多中心，阶段I，具有第二阶段扩张队列的剂量升级研究，以确定静脉内TKM-080301在具有晚期肝细胞癌的受试者中的安全性，药代动力学和初步抗肿瘤活性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Lessons Learned

机译：得到教训

著录项

来源
《The oncologist》 |2019年第6期|共7页
作者
El Dika Imane; Lim Ho Yeong; Yong Wei Peng; Lin Chia-Chi; Yoon Jung-Hwan; Modiano Manuel; Freilich Bradley; Choi Hye Jin; Chao Tsu-Yi; Kelley Robin K.; Brown Joanne; Knox Jennifer; Ryoo Baek-Yeol; Yau Thomas; Abou-Alfa Ghassan K.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr 400 East 66th St New York NY 10065 USA;

Samsung Med Ctr Seoul South Korea;

Natl Univ Singapore Hosp Singapore Singapore;

Natl Taiwan Univ Hosp Taipei Taiwan;

Seoul Natl Univ Hosp Seoul South Korea;

Arizona Oncol Associates PC Tucson AZ USA;

Kansas City Res Inst LLC Kansas City MO USA;

Yonsei Univ Hlth Syst Severance Hosp Seoul South Korea;

Taipei Med Univ Shuang Ho Hosp Taipei Taiwan;

Univ Calif San Francisco San Francisco CA 94143 USA;

Arbutus Biopharma Inc Warminster PA USA;

Princess Margaret Hosp Toronto ON Canada;

Asan Med Ctr Seoul South Korea;

Queen Mary Hosp Hong Kong Peoples R China;

Mem Sloan Kettering Canc Ctr 400 East 66th St New York NY 10065 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma [J] . El Dika Imane, Lim Ho Yeong, Yong Wei Peng, The oncologist . 2019,第6期

机译：开放标签，多中心，阶段I，具有第二阶段扩张队列的剂量升级研究，以确定静脉内TKM-080301在具有晚期肝细胞癌的受试者中的安全性，药代动力学和初步抗肿瘤活性
2. An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma [J] . Abou-Alfa G. K., Yoon J. H., Modiano M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：在晚期肝细胞癌患者中进行的IV TKM-080301的开放标签，多中心，I / II期剂量递增研究
3. An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma [J] . Abou-Alfa G. K., Yoon J. H., Modiano M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：具有晚期肝细胞癌的受试者IV TKM-080301的开放标签，多中心，I / II，剂量升级研究
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. An Open‐Label Multicenter Phase I Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety Pharmacokinetics and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma [O] . Imane El Dika, Ho Yeong Lim, Wei Peng Yong, 2019

机译：一项开放标签多中心I期II期扩展队列的剂量递增研究用于确定晚期肝细胞癌患者静脉TKM-080301的安全性药代动力学和初步抗肿瘤活性
7. Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors [O] . F. Janku, R. Abdul-Karim, A. Azad, 2020

机译：开放标签的初步结果，多中心阶段1/2剂量升级和Thor-707，一种新的Not-alpha IL-2，作为成人受试者的单一剂，具有晚期或转移性实体肿瘤

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅